Microcystic stromal tumor (MCST) of the ovary is a rare subtype of ovarian tumor first described in 2009. Although high nuclear expression of β-catenin and β-catenin gene (CTNNB1) mutation are related with ovarian MCST, the origin and genetic background of ovarian MCST remain unclear. In this study, two cases of ovarian MCST are presented. Microscopically, the tumors showed a microcystic pattern and regions with lobulated cellular masses with intervening hyalinized, fibrous stroma. Tumor cells of both cases were stained with CD10, vimentin, and Wilms tumor 1. Genetic analysis was performed and β-catenin gene (CTNNB1) mutation in exon 3 was detected in both cases. This is the first report in regards of detecting CTNNB1 mutation in ovarian MCST through the use of pyrosequencing (a novel sequencing technique).
Introduction
Microcystic stromal tumor (MCST) of the ovary is a rare subtype of ovarian tumor with less than 30 cases reported worldwide [1] [2] [3] [4] [5] [6] . It is a new disease entity first described by Irving and Young in 2009 [1] based on 16 cases of uncategorized ovarian tumors. The distinctive histological characteristics of the tumor include: a microcystic pattern and regions with lobulated cellular masses with intervening, sometimes hyalinized, fibrous stroma; an absence of morphologic features enabling any other specific diagnosis in the sex cord-stromal category; an absence of epithelial elements; and an absence of teratomatous or other germ cell elements. Immunohistochemically, MCST cells are strongly positive for CD10, vimentin, and Wilms tumor 1, and negative for sex-cord stromal markers (α-inhibin and calretinin) and epithelial membrane antigen.
The origin and genetic background of ovarian MCST is still unclear. In 2011, Maeda et al. [2] reported β-catenin gene (CTNNB1) mutation and high nuclear expression of β-catenin in two cases of ovarian MCST. Several more reports that mutation in β-catenin gene (CTNNB1) is related with ovarian MCST followed [3] [4] [5] [6] . In this study, we report two cases of ovarian MCST, along with the β-catenin gene (CTNNB1) mutation in exon 3 that was also detected in both cases. This is the first report of the detection of CTNNB1 mutation in ovarian MCST using pyrosequencing. ment because of lower abdominal discomfort for a week. After physical evaluation, the patient underwent computed tomography (CT), which showed an 18×12-cm multilocular cystic mass originating from the left adnexa. The cyst presented features of benign epithelial ovarian cyst such as smooth outer wall and thin internal sepation (Fig. 1A) . Serum levels of CA-125 and CA-19-9 were within normal limits. The patient underwent laparoscopic salpingo-oopherecomy. Due to material insufficiency, the result of intraoperative frozen biopsy was non-diagnostic. Finally, the patient was diagnosed as MCST.
Case report
No adjuvant treatment was performed. The patient is currently free of disease after 8 months from surgery.
Case 2
A 31-year-old woman, gravida 0, who presented with a palpable mass at lower abdomen was referred to a tertiary healthcare institution. Pelvis CT and pelvis magnetic resonance imaging revealed a 24-cm-sized left ovarian mass with solid and cystic portion. The mass presented thick outer wall with irregular margin (Fig. 1B, C) . For further examination, positron emission tomography (PET)-CT was performed. On PET-CT, intense 18-fluoro-2-doxy-D-glucose uptake was shown at 24-cm-sized left ovarian mass and several lymph nodes in aortocaval space and left paraaortic space, which suggested ovarian malignancy with lymph node metastasis ( Fig. 1D-F) . Elevation of tumor markers reflected ovarian epithelial tumor. CA-125 was elevated at 205.3 IU/L (normal range, 0 to 35 IU/L). Human epididymis protein 4 was slightly elevated at 69.1 IU/ L (normal range, 0 to 67 IU/L). The patient underwent staging laparotomy including left salpingo-oopherecomy, paraaortic lymph node sampling, and abdominal peritonectomy. The result of intraoperative frozen pathology was "favoring sex cord stromal tumor". After the immunohistochemical examination, the patient was finally diagnosed as MCST and paraaortic lymph nodes were free from tumor. Without adjuvant therapy, she is currently free of disease after 3 months after surgery and scheduled for follow-up after 6 months.
Pathologic findings
Grossly, the resected specimen of case 1 was fragmented tumor tissues (18×12 cm), consisting of a relatively well-circumscribed cystic mass, necrotic material, and blood clots ( Fig.  2A) . The cystic wall containing tumor tissue showed a smooth outer surface and internal thin, fibrous septae. No definite solid lesion was identified. The specimen of case 2 was a wellcircumscribed, multilobulated cystic mass measuring 20×14 cm and weighing 80 g (Fig. 2B ). Extensive tumor necrosis was identified within the mass. Multifocal solid lesions were identified. There was no capsular involvement. Microscopically, the tumor consisted of three histologic components: solid sheets of tumor cells, numerous microcysts, and intervening bundles of hyalinized fibrous bands within the stroma (Fig. 2C, D) . The variable-sized microcysts were lined with bland-appearing tumor cells (Fig. 2E, F) . The individual tumor cells had uniform, small, round nuclei with inconspicuous nucleoli and abundant granular, eosinophilic cytoplasm. Immunohistochemically, the tumor cells exhibited cytoplasmic immunoreactivity for CD10, CD99, and vimentin (Fig. 3A) , as well as diffuse and strong nuclear immunoreactivity for β-catenin (Fig. 3B) .
In addition, pyrosequencing revealed a point mutation (S33C) in exon 3 of CTNNB1 (Fig. 3C, D) , confirming the diagnosis of ovarian MCST.
Discussion
MCST of the ovary is a newly categorized ovarian tumor first described by Irving and Young in 2009 [1] based on 16 cases of uncategorized ovarian tumors. Although MCST is sometimes mistaken for the coma due to its thick hyalinized fibrous band, it has distinctive microscopic features of solid, microcystic or macrocystic patterns, and uniform and round tumor cells with low number of mitotic figures [4, 7] . Behavior of the tumor is not well known because of limited follow-ups. The available information would suggest it is likely benign in most cases [1] .
As the name hints, the origin of ovarian MCST is thought to be stroma. Irving and Young suggested possibility of stromal origin by excluding other origins. MCST's characteristic immunoprofile (CD10-positive, vimentin-positive, and epithelial membrane antigen-negative) and ultrastructural analysis also supports the possibility of stromal origin. However, Maeda et al. [2] insisted MCST should be classified as "tumors of uncertain origin" considering the pluripotency of the tumor cells.
In 2011, Maeda et al. [2] reported β-catenin gene (CTNNB1) mutation and high nuclear expression of β-catenin in two cases of ovarian MCST. Since 2011, eleven more MCST cases were reported, with β-catenin gene (CTNNB1) mutation confirmed in eight cases [3] [4] [5] [6] . β-catenin is a regulatory protein in 
